DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Active ingredient: Rituximab - Brands, Medical Use, Clinical Data

Brands, Medical Use, Clinical Data

Drug Category

  • Antineoplastic Agents

Dosage Forms

  • Solution (IV infusion)

Brands / Synonyms

AntiCD20; Ig gamma-1 chain C region; Rituxan; Rituxan (Genentech Inc)

Description

Rituxan is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes. The antibody is an IgG1 kappa immunoglobulin containing murine light- and heavy-chain variable region sequences and human constant region sequences. Rituximab is composed of two heavy chains of 451 amino acids and two light chains of 213 amino acids

Indications

For treatment of B-cell non-Hodgkins lymphoma (CD20 positive)

Pharmacology

Rituxan binds to the CD20 antigen, which is predominantly expressed on mature B cells and on >90% of B-cell non-Hodgkin's lympohomas. The antibody leads to selective killing of B-cells.

Mechanism of Action

Binds to the CD20 antigen which is found on mature B lymphocytes. The Fc domain recruits immune effector functions to mediate B-cell lysis. The antibody appears to induce apoptosis, antibody mediated cytotoxicity and complement-dependent cytotoxicity.

Absorption

Not Available

Toxicity

Not Available

Biotrnasformation / Drug Metabolism

Most likely removed by opsonization via the reticuloendothelial system when bound to B lymphocytes, or by human antimurine antibody production

Contraindications

Not Available

Drug Interactions

Not Available

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014